BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19119459)

  • 1. A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.
    Kim IS; Park ES; Lim JY; Ki CS; Chi HS
    J Korean Med Sci; 2008 Dec; 23(6):1105-8. PubMed ID: 19119459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
    Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
    Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
    Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
    J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.
    Ono R; Hasegawa D; Hirabayashi S; Kamiya T; Yoshida K; Yonekawa S; Ogawa C; Hosoya R; Toki T; Terui K; Ito E; Manabe A
    Eur J Pediatr; 2015 Apr; 174(4):525-31. PubMed ID: 25266042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
    Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
    Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
    Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
    Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
    Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Druschel CM; Sandoval C
    Blood; 2007 Sep; 110(6):2128-31. PubMed ID: 17576817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.
    Xu G; Kanezaki R; Toki T; Watanabe S; Takahashi Y; Terui K; Kitabayashi I; Ito E
    Leukemia; 2006 Jun; 20(6):1002-8. PubMed ID: 16628190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
    Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
    J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
    Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
    Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Megakaryocytic Leukemia.
    McNulty M; Crispino JD
    Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31548219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute megakaryoblastic leukemia with a novel GATA1 mutation in a second trimester stillborn fetus with trisomy 21.
    Bonometti A; Lobascio G; Boveri E; Cesari S; Lecca M; Arossa A; Spinillo A; Errichiello E; Paulli M
    Leuk Lymphoma; 2021 Sep; 62(9):2276-2279. PubMed ID: 33783296
    [No Abstract]   [Full Text] [Related]  

  • 18. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
    Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
    Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
    Terui K; Toki T; Taga T; Iwamoto S; Miyamura T; Hasegawa D; Moritake H; Hama A; Nakashima K; Kanezaki R; Kudo K; Saito AM; Horibe K; Adachi S; Tomizawa D; Ito E
    Genes Chromosomes Cancer; 2020 Mar; 59(3):160-167. PubMed ID: 31606922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular insights into Down syndrome-associated leukemia.
    Vyas P; Crispino JD
    Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.